Recent Quotes (30 days)

You have no recent quotes
chg | %

Elite Pharmaceuticals Inc  

(Public, OTCBB:ELTP)   Watch this stock  
Find more results for elite
0.275
+0.001 (0.40%)
Nov 21 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.26 - 0.28
52 week 0.09 - 0.97
Open 0.27
Vol / Avg. 1.45M/1.14M
Mkt cap 164.07M
P/E     -
Div/yield     -
EPS -0.14
Shares 596.61M
Beta 0.43
Inst. own 0%
Nov 19, 2014
Q2 2015 Elite Pharmaceuticals Inc Earnings Call
Nov 18, 2014
Q2 2015 Elite Pharmaceuticals Inc Earnings Release
Sep 9, 2014
Elite Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 1701.65% -2098.83%
Operating margin -323.25% -114.83%
EBITD margin - -103.94%
Return on average assets 358.37% -544.96%
Return on average equity - -
Employees 38 -
CDP Score - -

Address

165 Ludlow Avenue
NORTHVALE, NJ 07647
United States - Map
+1-201-7502646 (Phone)
+1-201-7502755 (Fax)

Website links

Description

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufactures of oral, controlled-release products, using technology and the development and manufacture of generic pharmaceuticals. Elite has four products: Phentermine 37.5 milligram tablets, Methadone 10 milligram tablets, Lodrane D Immediate Release capsules and Hydromorphone Hydrochloride 8 milligram tablets. During the fiscal years ended March 31, 2012 (Fiscal 2011), the Company manufactured and sold Lodrane 24 and Lodrane 24D (the Lodrane Extended Release Products). The Company has a pipeline of additional generic drug candidates under active development, including, without limitation, ELI-154, a once-a-day oxycodone product and ELI-216, an abuse resistant oxycodone product which utilizes the Company�s propriety formulation for abuse resistant products utilizing the pharmacological approach (Elite�s Abuse Resistant Technology).

Officers and directors

Jerry I Treppel Chairman of the Board
Age: 60
Nasrat Hakim President, Chief Executive Officer, Director
Age: 53
Carter J. Ward CPA Chief Financial Officer, Treasurer, Secretary
Age: 50
Ashok G. Nigalaye Ph.D. Chief Scientific Officer, Director
Age: 62
Jeenarine Narine Director
Age: 64
Barry H. Dash Ph.D. Independent Director
Age: 83
Jeffrey A. Whitnell Independent Director
Age: 58